Article

Immunotherapy: The Meta-Analyses. What have we Learned?

Department of Allergy and Respiratory Medicine, Imperial College, National Heart and Lung Institute, Royal Brompton and Harefield Trust, Dovehouse Street, London SW3 6LY, UK.
Immunology and allergy clinics of North America (Impact Factor: 1.82). 05/2011; 31(2):159-73, vii. DOI: 10.1016/j.iac.2011.02.002
Source: PubMed

ABSTRACT

Meta-analysis is a powerful tool for evaluating the efficacy of a therapeutic intervention, and has clearly demonstrated that specific allergen immunotherapy (SIT) is effective for treating allergic rhinitis and asthma. Future research needs to focus on specifying the most effective forms of SIT for specific populations and allergens, using validated clinical outcomes, studying long-term outcomes (particularly the potential disease-modifying effect of immunotherapy), and assessing outcomes regarding health economics. The safety profile of SIT should be evaluated using international guidelines and terminology, and needs to include high-quality surveillance data.

0 Followers
 · 
8 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The role of allergen-specific immunotherapy in asthma (AIT) is still a matter of debate. Actually, many controlled clinical trials have proved efficacy and safety of AIT in asthma, and some published meta-analyses, despite some methodological weaknesses, have confirmed these findings, the most recent and convincing being a meta-analysis on injection AIT studies. For sublingual AIT evidences do exist, but SLIT meta-analyses are mostly questioned due to some biases and inconsistencies. Most of these arise from methodological problems in single studies, usually small, underpowered and carried out with mixed populations. The main need, therefore, is to perform AIT clinical studies only in patients with asthma and following standardized protocols, as recommended by international Guidelines. Studies of AIT in asthma should also focus more on the long term and preventive effects of the treatment, rather than considering only the immediate efficacy on allergic symptoms. Furthermore, specific asthma features, such as lung function, bronchial reactivity, asthma control and exacerbations, should be included among the study outcomes.
    Full-text · Article · Aug 2011 · European annals of allergy and clinical immunology
  • [Show abstract] [Hide abstract]
    ABSTRACT: To summarize novel insights into the immunological mechanisms of sublingual immunotherapy (SLIT). Within the recent decades, several alternative noninvasive allergen application strategies have been investigated in allergen-specific immunotherapy (AIT), of which intra-oral allergen application to sublingual mucosa has been proven to be well tolerated and effective. To date, SLIT is widely accepted by most allergists as an alternative option to conventional subcutaneous immunotherapy (SCIT). Although detailed immunological mechanisms remain to be elucidated, much scientific effort has been made to shed some light on local and systemic immunological responses to SLIT in mice as well as humans. Only a few studies focused on the detailed mechanisms following allergen application to the oral mucosa as part of the sophisticated mucosal immunological network. Within this network, the pro-tolerogenic properties of local antigen-presenting cells (APCs) such as dendritic cells - which are able to enforce tolerogenic mechanisms and to induce T-cell immune responses - play a central role. Further on, basic research focused not only on the immune response in nasal and bronchial mucosa but also on the systemic T-cell immune response. Thus, much exiting data have been published providing a better understanding of immunological features of SLIT but far more investigations are necessary to uncover further exciting details on the key mechanisms of SLIT.
    No preview · Article · Dec 2011 · Current Opinion in Allergy and Clinical Immunology
  • [Show abstract] [Hide abstract]
    ABSTRACT: At least 1 in 200 people have suffered a severe allergic reaction to a sting from a bee, wasp, or ant, and insect stings are the second most common cause of fatal allergic reactions in some countries. Treatment with insect venom, usually given by a course of injections (called venom immunotherapy), is thought to reduce the risk of allergic reactions to an insect sting. In this review, we evaluated the effectiveness of venom immunotherapy for preventing allergic reactions to insect stings. From analysis of 7 studies, which included 392 participants, we found that this treatment reduces the chance of having a serious allergic reaction to an insect sting by 90%, a consistent finding between studies. Venom immunotherapy also significantly improves the quality of life of people who have had a serious allergic reaction to an insect sting by reducing anxiety and possible limitation of activities caused by fear of insects. However, almost 1 in 10 people treated with venom immunotherapy during the trials had an allergic reaction to their treatment. We were unable to find out whether venom immunotherapy prevents fatal allergic reactions to insect stings, because these are so rare. The decision whether to start venom immunotherapy depends on an accurate diagnosis, followed by careful assessment of a person's risk of having another allergic reaction to a sting, the degree to which the insect sting allergy affects their quality of life, and the risk of an allergic reaction to their treatment.
    No preview · Article · Oct 2012 · Cochrane database of systematic reviews (Online)
Show more